For the year ending 2025-12-31, CALC had $3,585K increase in cash & cash equivalents over the period. -$21,206K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -29,562 |
| Stock-based compensation expense | 2,971 |
| Depreciation | 46 |
| Change in the fair value of warrant liability | 5,223 |
| Change in the fair value of promissory note | 777 |
| Promissory note issuance costs | -336 |
| Transaction costs associated with warrants | 0 |
| Accretion of discount on short-term investments | 345 |
| Change in unrealized losses on investments | 1 |
| Prepaid expenses, other current and non-current assets | -536 |
| Accounts payable | -840 |
| Accrued expenses and other liabilities | -319 |
| Net cash used in operating activities | -21,178 |
| Purchase of investments | 15,916 |
| Maturity of investments | 25,495 |
| Purchases of property and equipment | 28 |
| Net cash provided by (used in) investing activities | 9,551 |
| Proceeds from issuance of common stock, net of issuance costs | 8 |
| Proceeds from exercise of stock options | 25 |
| Proceeds from issuance of promissory note, net | 9,664 |
| Proceeds from issuance of common stock from atm facility, net of issuance costs | 5,515 |
| Net cash provided by financing activities | 15,212 |
| Net increase in cash and cash equivalents | 3,585 |
| Cash and cash equivalents at beginning of period | 7,935 |
| Cash and cash equivalents at end of period | 11,520 |
CalciMedica, Inc. (CALC)
CalciMedica, Inc. (CALC)